Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

Topics of Professional Interest:
  • HIV/HCV coinfection liver disease pathogenesis
  • HCV therapeutics
  • HIV/HCV healthcare utilization
  • Clinical trials of antiviral drugs
  • HIV/HCV natural history and clinical outcomes
Current Professional Summary:

Dr Susanna Naggie is an Associate Professor of Medicine at Duke University School of Medicine. She holds a joint appointment in the Section of GI/Hepatology Research at the Duke Clinical Research Institute where she is involved in Phase I-III Clinical Trials. She staffs two HIV/HCV coinfection multidisciplinary clinics at Duke and the Durham VA. She serves as an inpatient attending physician on ID consults and general internal medicine at the Durham VA Medical Center.

Committees and Organizations:
  • IAS–USA Viral Hepatitis Co-Chair
  • HIV Integrated Learning Modules: Achieving Performance Improvement through Collaboration (VISION) Steering Committee
  • Infectious Diseases Society of America (2008-present)
  • American Association for the Study of Liver Diseases (2010-present)
  • European Association for the Study of the Liver (2010-present)
  • International AIDS Society (2010-present)
Honors and Awards:
  • AMA/WPC Physicians Mentor Recognition (2007)
  • General Medicine Teaching Award, Duke General Medicine Wards (2006)
  • Golden Apple Attending Teaching Award Nominee (2006)
Education:
  • University of Maryland College Park, BS, Chemical Engineering (1998)
  • Johns Hopkins University School of Medicine, MD, Medicine (2002)
  • Duke University Medical Center, Resident, Internal Medicine (2005)
  • Duke University Medical Center, Fellow, Infectious Diseases (2009)
  • Duke University Clinical Research Training Program, MHS, Clinical Research (2010)
Selected Publications:
  1. Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 2010;(In press).
  2. Rallon NI, Restrepo C, Naggie S, et al. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS. 2011;25:269-271.
  3. Medrano J, Neukam K, Rallón N, et al. Modeling the probability of sustained virological response to Therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis. 2010;51:1209-1216.
  4. Thompson AJ, Muir AJ, Sulkowski MS, et al. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. Hepatology. 2010;52:2243-2244.
  5. Naggie S, Patel K, McHutchison J. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother. 2010;65:2063-2069.
  6. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139:1181-1189.
  7. Naggie S, Frederick J, Pien BC, et al. Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA. Infection. 2010;38:297-300.
  8. Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23-F29.
  9. Naggie S, Hicks C. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J Antimicrob Chemother. 2010;65:1094-1099.
  10. Naggie S, Hseih T, Reckleff J, Castellano J, Hicks CB. Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS. Clin Infect Dis. 2009;49:1619-1620.

Presentations

Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes

An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

Hepatitis C Virus Infection: Looking Beyond the Interferon Alfa Era

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management